肿瘤防治研究2012，Vol.39Issue(9)：1136-1138,3.DOI:10.3971/j.issn.1000-8578.2012.09.020
甲酰四氢叶酸钙联合5-氟尿嘧啶二线治疗晚期乳腺癌
Combination of Calcium Folinate and 5-Fluorouracil As Second-line Treatment for Advanced Breast Cancer
摘要
Abstract
Objective To study the clinical efficiency and safety of calcium folinate combined with 5-flu-orouracil in advanced breast cancer patients. Methods Thirty-one advanced breast cancer patients were enrolled; with median age was 48. 0 years(27—66 years) ,who had progressed diseases after treatments of anthracycline compounds and paclitaxel. Estrogen receptor(ER) and(or) progesterone receptor(PR) were positive in 12 cases(ER+ ,9 cases;PR+ ,5 cases;ER+ and PR+ ,2 cases),ER and PR were negative in 19 cases. The patients were treated with CF[150 mg/(m2 · d)] and 5-Fu[(600 mg/(m2 · d)] by venous infusion for more than 12 hours with D1—5. This therapeutic regimen was 28 days per 1 cycle. Results Complete response(CR) ,partial response(PR) ,stable disease (SD) and progressive disease (PD) was a-chieved in 2 patients(6. 4%),7 patients(22. 58%) , 6 patients ( 19. 35% ) and 16 patients (51. 61 %), respectively. Overall response rate(CR+ PR) was 29.0% and the clinical benefit rate(CR+ PR + SD) was 48. 4%. It was more obvious that patients with negative hormone receptor had increased response rate(P <0. 05). The median duration of response was 2. 3 months(95%CI: 1. 1~4. 1) and median survival time was 9. 5 months(95%CI:4. 7—14. 8). The quality of life was improved in 15 cases(48. 4%) .stable in 6 cases(19. 4%) and decreased in 10 cases(32. 3%). The main toxic effects were gastrointestinal side-effect (11 cases) ,bone marrow suppression(4 cases) and stomatitis(9 cases). Conclusion The combination of CF and 5-Fu given by continuous venous infusion every 4 weeks was active in terms of objective response rate against advanced breast cancer with well-tolerance.
关键词
晚期乳腺癌/甲酰四氢叶酸钙/5-氟尿嘧啶Key words
Advanced breast cancer/Calcium folinate/5-fluorouracil分类
医药卫生引用本文复制引用
冯尧军,吴新红,何建平,马彪..甲酰四氢叶酸钙联合5-氟尿嘧啶二线治疗晚期乳腺癌[J].肿瘤防治研究,2012,39(9):1136-1138,3.
